ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Eton Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$49.22−1.09 (-2.17%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 126.2
- Dividend yield
- –
Share price
+$31.04 (+170.7%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Eton Pharmaceuticals, Inc. grew revenue 81.5% to $105.60M over the twelve months to Jun 30, 2026. Free cash flow was $14.73M, up 20.5% from a year earlier.
Revenue
$105.60M
+81.5% vs. a year earlier
Operating income
$16.31M
TTM Q2 2026
Free cash flow
$14.73M
+20.5% vs. a year earlier
EPS, diluted
$0.39
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.61B
- P/E ratio
- 126.2
- Price to sales
- 15.28
- Price to book
- 34.64
- Dividend yield
- –
- Free cash flow yield
- 0.91%
Fundamentals
- Revenue
- $105.60M
- Net income
- $12.69M
- EPS, diluted
- $0.39
- Free cash flow
- $14.73M
- Book value per share
- $1.42
- Diluted shares
- 33M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$105.60M+81.5% YoY
Gross profit
$61.10M+76.8% YoY
Operating income
$16.31M
Net income
$12.69M
EPS, diluted
$0.39
Free cash flow
$14.73M+20.5% YoY
Reported periodTrailing twelve months